Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.

Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G.

Blood. 2013 Jan 3;121(1):159-69. doi: 10.1182/blood-2012-05-428573.

2.

Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.

Russ AC, Sander S, Lück SC, Lang KM, Bauer M, Rücker FG, Kestler HA, Schlenk RF, Döhner H, Holzmann K, Döhner K, Bullinger L.

Haematologica. 2011 Dec;96(12):1783-91. doi: 10.3324/haematol.2011.046888.

3.

The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression.

Kuo YY, Hou HA, Chen YK, Li LY, Chen PH, Tseng MH, Huang CF, Lee FY, Liu MC, Liu CW, Chou WC, Liu CY, Tang JL, Yao M, Tien HF.

Haematologica. 2014 Dec;99(12):1799-807. doi: 10.3324/haematol.2014.107821.

4.

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD.

J Clin Oncol. 2008 Nov 1;26(31):5078-87. doi: 10.1200/JCO.2008.17.5554. Erratum in: J Clin Oncol. 2008 Dec 20;26(36):6021.

5.

C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia.

Hughes JM, Legnini I, Salvatori B, Masciarelli S, Marchioni M, Fazi F, Morlando M, Bozzoni I, Fatica A.

Oncotarget. 2015 Jul 30;6(21):18534-44.

6.

Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.

Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barsyte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KV, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, Al-Awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G.

Nat Chem Biol. 2015 Aug;11(8):571-8. doi: 10.1038/nchembio.1859. Erratum in: Nat Chem Biol. 2015 Oct;11(10):815.

7.

MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets.

Su R, Lin HS, Zhang XH, Yin XL, Ning HM, Liu B, Zhai PF, Gong JN, Shen C, Song L, Chen J, Wang F, Zhao HL, Ma YN, Yu J, Zhang JW.

Oncogene. 2015 Jun;34(25):3226-39. doi: 10.1038/onc.2014.274.

PMID:
25174404
8.

Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia.

Katzerke C, Madan V, Gerloff D, Bräuer-Hartmann D, Hartmann JU, Wurm AA, Müller-Tidow C, Schnittger S, Tenen DG, Niederwieser D, Behre G.

Blood. 2013 Oct 3;122(14):2433-42. doi: 10.1182/blood-2012-12-472183.

9.

C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.

Pulikkan JA, Peramangalam PS, Dengler V, Ho PA, Preudhomme C, Meshinchi S, Christopeit M, Nibourel O, Müller-Tidow C, Bohlander SK, Tenen DG, Behre G.

Blood. 2010 Dec 16;116(25):5638-49. doi: 10.1182/blood-2010-04-281600.

10.

Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.

Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G.

J Hematol Oncol. 2013 Mar 16;6:21. doi: 10.1186/1756-8722-6-21.

11.

C/EBPα in normal and malignant myelopoiesis.

Friedman AD.

Int J Hematol. 2015 Apr;101(4):330-41. doi: 10.1007/s12185-015-1764-6. Review.

12.

Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia.

Khanna-Gupta A, Abayasekara N, Levine M, Sun H, Virgilio M, Nia N, Halene S, Sportoletti P, Jeong JY, Pandolfi PP, Berliner N.

J Biol Chem. 2012 Sep 21;287(39):32728-37.

13.

Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.

Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu YZ, Alachkar H, Anghelina M, Dorrance A, Curfman J, Bloomfield CD, Medeiros BC, Perrotti D, Lee LJ, Lee RJ, Caligiuri MA, Pichiorri F, Croce CM, Garzon R, Guzman ML, Mendler JH, Marcucci G.

Leukemia. 2015 Oct;29(10):1981-92. doi: 10.1038/leu.2015.106.

14.

Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.

Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci G.

Clin Cancer Res. 2013 May 1;19(9):2355-67. doi: 10.1158/1078-0432.CCR-12-3191.

15.

Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.

Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Zimmermann M, Peeters JK, Valk PJ, Balgobind BV, Sonneveld E, Kaspers GJ, de Bont ES, Trka J, Baruchel A, Creutzig U, Pieters R, Reinhardt D, Zwaan CM.

Haematologica. 2011 Mar;96(3):384-92. doi: 10.3324/haematol.2010.031336.

16.

ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia.

Damm F, Wagner K, Görlich K, Morgan M, Thol F, Yun H, Delwel R, Valk PJ, Löwenberg B, Heuser M, Ganser A, Krauter J.

Br J Haematol. 2012 Jul;158(2):208-15. doi: 10.1111/j.1365-2141.2012.09144.x.

PMID:
22568493
17.

Complexity of miR-223 regulation by CEBPA in human AML.

Eyholzer M, Schmid S, Schardt JA, Haefliger S, Mueller BU, Pabst T.

Leuk Res. 2010 May;34(5):672-6. doi: 10.1016/j.leukres.2009.11.019.

PMID:
20018373
18.

miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.

Ovcharenko D, Stölzel F, Poitz D, Fierro F, Schaich M, Neubauer A, Kelnar K, Davison T, Müller-Tidow C, Thiede C, Bornhäuser M, Ehninger G, Brown D, Illmer T.

Exp Hematol. 2011 Oct;39(10):1030-1042.e7. doi: 10.1016/j.exphem.2011.07.008.

PMID:
21784052
19.

Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.

Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Meijer J, van Oosterhoud S, van Putten WL, Valk PJ, Berna Beverloo H, Tenen DG, Löwenberg B, Delwel R.

Hematol J. 2003;4(1):31-40.

PMID:
12692518
20.

BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.

Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA, Calabretta B.

Nat Genet. 2002 Jan;30(1):48-58.

PMID:
11753385
Items per page

Supplemental Content

Support Center